Why is UiPath stock down 16.9% today?

Traders Union
All News
Stocks
Uipath slides 16.99% today to $15.13

Highlights

UiPath stock reported Q2 fiscal 2027 revenue of $410.3 million, up 13% year over year, with adjusted earnings of $0.15 per share in line with analyst forecasts.
The company increased its full-year revenue guidance to $1.789 to $1.794 billion and achieved GAAP profitability for a fourth consecutive quarter.
Shares dropped 16.99% to $15.13 under selling pressure, with mixed technical signals and a projected five-day range of $14.58 to $15.68.

Guidance increased yet price under pressure as optimism meets skepticism

UiPath Inc. reported Q2 fiscal 2027 revenue of $410.3 million, a 13% year-over-year increase, with adjusted earnings of $0.15 per share matching analyst expectations. The company raised its fiscal 2027 revenue guidance to a range of $1.789–$1.794 billion and projected non-GAAP operating income of approximately $445 million. Annual recurring revenue climbed 12% year-over-year to $1.938 billion and GAAP profitability was achieved for the fourth consecutive quarter. Secondary developments included the launch of AI-driven product enhancements and expanded strategic partnerships, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees technical fragility despite UiPath’s headline revenue beat and positive earnings. He notes that the near 17% drop reflects deep skepticism over long-term growth and the sustainability of recent AI initiatives. Kharitonov highlights persistent overbought momentum signals and weak demand on heavy selling flows. He remains wary of the downside gap left open after results, suggesting limited near-term recovery potential. "Short-lived rallies may only offer exit opportunities until the price structure proves its resilience at key supports," he warns.

Viktoras Karapetjanc, expert at Traders Union, emphasizes UiPath’s robust fundamentals following a strong revenue increase and sustained GAAP profitability. He highlights upgraded guidance and rising annual recurring revenue as signals of operational momentum and ongoing business transformation. Karapetjanc considers the pullback a temporary reset within a bullish structure above 50- and 200-day averages. "I see further growth on the horizon as product innovation and improved guidance fuel investor confidence," he states.

Sholanke Dele, market strategist, interprets the steep selloff as a warning of shaky sentiment around UiPath’s future trajectory. He observes that strong results failed to inspire conviction, with news flow unable to counteract widespread profit-taking. Dele points to market uncertainties weighing heavily, particularly given mixed momentum readings and volatility spikes. "Caution is warranted — upside scenarios appear vulnerable unless macro sentiment shifts materially," he advises.

Short-term weakness intensifies amid bullish trend and conflicting signals

UiPath is trading below its 20-day moving average at $16.67 but remains above both the 50-day at $13.79 and the 200-day at $12.88, indicating short-term selling pressure alongside a medium- and longer-term bullish tilt. The nearest resistance is set by the Ichimoku Kijun at $15.25, with support found at today’s low of $14.77. Momentum signals are mixed: the MACD and ADX are both bullish, yet RSI reads 71.21, CCI and Bull/Bear Power all flag overbought conditions, and intraday flows are dominated by sellers amid heightened volatility. The sharp daily decline to $15.13 with a significant downside gap leaves the price near session lows, highlighting persistent downside pressure despite conflicting momentum and oscillator signals.

Earlier, analysts noted that UiPath faced mounting downside risk as technical signals turned mixed and persistent selling pressure limited prospects for a near-term recovery. The latest trading action reinforces this cautious outlook, making the $15.25 resistance level a pivotal threshold for determining whether the current consolidation phase resolves to the upside or extends further weakness.

Source of Data: PATH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.